Purchase this article with an account.
Srinivas R Sadda; Biomarkers and endpoints for dry AMD trials. Invest. Ophthalmol. Vis. Sci. 2019;60(9):991. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Advances in OCT and OCT image analysis have yielded opportunities to better track the progression and evolution of non-neovascular age-related macular degeneration (AMD). This has allowed the indentification of novel OCT risk factors for progression of AMD which may create a path forward for early intervention trials. In addition, the development of OCT-based definitions for atrophy have created an opportunity for OCT to be used as a modality for assessing the late stages of dry AMD (atrophy). These new OCT-based approaches will be reviewed in this presentation.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only